We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
UK Health Security Agency's laboratories provide a comprehensive range of microbiological tests and services.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
The epidemiology, symptoms, diagnosis and management of monkeypox virus infections.
Paper on risk factors associated with places of enduring prevalence.
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
Biosecurity and hygiene standards to keep animals safe from bluetongue virus.
The characteristics, symptoms and epidemiology of parvovirus B19 (also known as slapped cheek syndrome, fifth disease, or erythma infectiosum).
Information for clinicians on the characteristics, diagnosis and epidemiology of infections caused by Chlamydia psittaci.
The epidemiology, symptoms, diagnosis and management of plague.
Information for patients, public and health care professionals.
The characteristics, diagnosis and epidemiology of Stenotrophomonas maltophilia.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).